Abatacept, a CTLA4-Ig fusion protein, attenuates T cell activation by inhibiting the CD80/CD86–CD28 costimulatory pathway that is required for the proper T cell activation and thus displays beneficial effects in the treatment of rheumatoid arthritis (RA) [1]. This evidence concerns the gene CD80 and rheumatoid arthritis.